Page results
-
Art and creativity can be a real tonic for health, says UCLH arts curator Guy Noble.
-
In a joint public appearance, the trio, who are Honorary Patrons of Teenage Cancer Trust, visited the ward to meet young patients and thank staff for their work.
-
Having proton beam therapy: information for children aged 9-12 patient information
-
A new study at UCLH and UCL aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumour.
-
This information is for patients having gynaecology surgery who may also need bowel (colorectal) surgery as part of their cancer treatment.
-
A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.
-
This page explains what spasticity is. It contains information on botulinum toxin and its use to treat conditions such as spasticity and dystonia which can occur after a stroke or brain injury.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
The Neurorehabilitation Unit (NRU) at The National Hospital for Neurology and Neurosurgery (NHNN) has been refurbished with funding from The National Brain Appeal to provide new facilities and additional space, transforming it into a more therapeutic environment.
File results
-
FOI/2022/0207 - Patient treatment with Nivolumab
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A